
Invacare Corporation IVC
Quarterly report 2023-Q1
added 05-15-2023
Invacare Corporation Book Value 2011-2026 | IVC
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Invacare Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 771 M | 910 M | 946 M | 309 M | 359 M | 423 M | 422 M | 463 M | 565 M | 671 M | 621 M | 627 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 946 M | 309 M | 591 M |
Quarterly Book Value Invacare Corporation
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 762 M | 771 M | 758 M | 813 M | 867 M | 910 M | 922 M | 974 M | 936 M | 946 M | 946 M | 886 M | 946 M | 852 M | 852 M | 852 M | 852 M | 886 M | 886 M | 886 M | 886 M | 1.07 B | 1.07 B | 1.07 B | 1.07 B | 904 M | 904 M | 904 M | 904 M | 838 M | 838 M | 838 M | 838 M | 964 M | 964 M | 964 M | 964 M | 1.1 B | 1.1 B | 1.1 B | 1.1 B | 1.26 B | 1.26 B | 1.26 B | 1.26 B | 1.28 B | 1.28 B | 1.28 B | 1.28 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.28 B | 758 M | 980 M |
Book Value of other stocks in the Medical devices industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Abiomed
ABMD
|
1.33 B | - | - | $ 17.2 B | ||
|
Acutus Medical
AFIB
|
-879 K | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | ||
|
Apollo Endosurgery
APEN
|
32.6 M | - | - | $ 475 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
196 M | - | - | $ 1.77 B | ||
|
Axonics Modulation Technologies
AXNX
|
570 M | - | - | $ 3.31 B | ||
|
AxoGen
AXGN
|
104 M | $ 31.85 | 2.68 % | $ 1.41 B | ||
|
Lianluo Smart Limited
LLIT
|
272 M | - | 24.59 % | $ 44.8 M | ||
|
Cognyte Software Ltd.
CGNT
|
217 M | $ 8.97 | -1.59 % | $ 644 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
25.5 M | - | -5.86 % | $ 30.6 M | ||
|
BIOLASE
BIOL
|
1.96 M | - | -13.19 % | $ 166 K | ||
|
BioSig Technologies
BSGM
|
-1.42 M | - | 37.08 % | $ 85.7 M | ||
|
Apyx Medical Corporation
APYX
|
26.9 M | $ 3.89 | -2.51 % | $ 135 M | ||
|
Alphatec Holdings
ATEC
|
776 M | $ 16.95 | -4.48 % | $ 2.42 B | ||
|
Bio-Rad Laboratories
BIO
|
6.57 B | $ 312.8 | -0.23 % | $ 8.83 B | ||
|
CONMED Corporation
CNMD
|
963 M | $ 41.19 | -0.91 % | $ 1.27 B | ||
|
EDAP TMS S.A.
EDAP
|
40.9 M | $ 3.69 | -9.12 % | $ 138 M | ||
|
Bruker Corporation
BRKR
|
1.82 B | $ 50.26 | 3.85 % | $ 7.49 K | ||
|
Boston Scientific Corporation
BSX
|
39.4 B | $ 91.09 | 3.43 % | $ 134 B | ||
|
Conformis
CFMS
|
54.2 M | - | - | $ 16.4 M | ||
|
Abbott Laboratories
ABT
|
81.4 B | $ 121.01 | -0.61 % | $ 211 B | ||
|
Cardiovascular Systems
CSII
|
249 M | - | 0.15 % | $ 844 M | ||
|
Cutera
CUTR
|
-172 M | - | -10.19 % | $ 1.99 M | ||
|
CryoLife, Inc.
CRY
|
58.1 M | - | -4.14 % | $ 702 M | ||
|
Dynatronics Corporation
DYNT
|
3.26 M | - | 14.99 % | $ 929 K | ||
|
CHF Solutions, Inc.
CHFS
|
6.23 M | - | 1.15 % | $ 34.5 M | ||
|
Soliton, Inc.
SOLY
|
243 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
2.61 B | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
229 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
30.4 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
52.2 M | - | - | $ 111 M | ||
|
GBS
GBS
|
2.81 M | - | -0.57 % | $ 7.12 M | ||
|
Intersect ENT, Inc.
XENT
|
550 M | - | - | $ 955 M | ||
|
InMode Ltd.
INMD
|
704 M | $ 13.79 | -1.11 % | $ 1.09 B | ||
|
Eargo
EAR
|
101 M | - | - | $ 10.2 M | ||
|
Electromed
ELMD
|
43.2 M | $ 27.84 | 0.04 % | $ 235 M | ||
|
Second Sight Medical Products
EYES
|
17.6 M | - | -0.97 % | $ 54.4 M | ||
|
Align Technology
ALGN
|
3.85 B | $ 165.75 | -3.35 % | $ 12.4 B | ||
|
Accuray Incorporated
ARAY
|
81.2 M | $ 0.81 | -3.78 % | $ 83.2 M | ||
|
Avinger
AVGR
|
-6.2 M | - | -20.74 % | $ 369 K | ||
|
ClearPoint Neuro
CLPT
|
25.4 M | $ 13.82 | -5.67 % | $ 374 M | ||
|
FONAR Corporation
FONR
|
146 M | $ 18.68 | 0.24 % | $ 122 M | ||
|
IRadimed Corporation
IRMD
|
86.8 M | $ 102.68 | 0.67 % | $ 1.3 B | ||
|
Integer Holdings Corporation
ITGR
|
1.62 B | $ 84.87 | -1.06 % | $ 2.85 B | ||
|
LivaNova PLC
LIVN
|
1.32 B | $ 62.45 | 0.55 % | $ 3.39 B | ||
|
Globus Medical
GMED
|
4.18 B | $ 92.68 | -0.85 % | $ 12.6 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
1.55 B | $ 11.98 | -3.51 % | $ 923 M | ||
|
Aziyo Biologics
AZYO
|
-38.6 M | - | 1.37 % | $ 20.5 M | ||
|
Pulmonx Corporation
LUNG
|
85.8 M | $ 1.78 | 0.28 % | $ 69.6 M |